A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 [0.03%]
中国获批的MET TKIs（萨沃利替尼、谷美替尼、维布替尼、特泊替尼、卡马替尼）用于MET外显子14跳变（METex14+）NSCLC治疗的简明回顾（截至2025年）
Yanyan Hu,Sai-Hong Ignatius Ou
Yanyan Hu
Splice site mutations around or within exon 14 of MET (METex14+) are rare, but are one of the common actionable driver mutations in elderly patients with non-small cell lung cancer (NSCLC). Globally, only two MET tyrosine kinase inhibitors ...
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib [0.03%]
克唑替尼、阿来替尼和塞瑞替尼序贯耐药后，Gilteritinib治疗伴脑转移的ALK+NSCLC患者的长期疗效：一例报告及Gilteritinib治疗文献回顾
Sai-Hong Ignatius Ou,Cathleen June Park,Zhaohui Liao Arter et al.
Sai-Hong Ignatius Ou et al.
Background: Despite the approval to date of 3 generations of ALK tyrosine kinase inhibitors (TKIs) and the clinical development of a 4th-generation ALK TKI, neladalkib (NVL-655), patients still eventually progress on sequ...
Gina N Duronio,Julien Sage
Gina N Duronio
The heterogeneous nature of cell populations in human tumors is a major contributor to tumor evolution, including and perhaps most importantly in response to treatment. Here, we review current knowledge on tumor heterogeneity and cell state...
Jing Wang,Layana Biglow,Megan Baumgart
Jing Wang
The identification of molecular driver mutations in non-small cell lung cancer (NSCLC) has changed the therapeutic landscape for this disease. Over the last 20 years, a growing number of driver mutations have been identified in addition to ...
Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study) [0.03%]
brigatinib治疗后仍对alectinib敏感的alk阳性的晚期非小细胞肺癌：brigalk2-gfpc 02-2019研究
Renaud Descourt,Florian Guisier,Maurice Pérol et al.
Renaud Descourt et al.
Background: Brigatinib and alectinib are next-generation anaplastic lymphoma kinase inhibitors (ALKis) showing efficacy against naïve and post-crizotinib-treated advanced ALK+ non-small-cell lung cancers (NSCLCs). Real-w...
Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Sensitive Response to Afatinib: A Case Report and Literature Review [0.03%]
表皮生长因子受体激酶区重复突变型肺腺癌阿法替尼敏感一例及文献复习
Shuangru Chen,Liting Zhang,Jun Wang et al.
Shuangru Chen et al.
Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare form of EGFR mutation. Unlike the classical mutations such as exon 19 deletion and exon 21 p.L858R point mutation, EGFR-KDD is a special type of large genomic r...
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients [0.03%]
吸烟者与非吸烟者肺鳞癌的基因组和转录组特征分析
Matteo Canale,Alessandra Virga,Davide Angeli et al.
Matteo Canale et al.
Purpose: Lung Squamous Cell Carcinoma (SCC) is a Non-Small Cell Lung Cancer (NSCLC) subtype with a strong clinical association with smoking habits and a very low incidence in never-smokers. Molecular profiling of SCC in n...
Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma [0.03%]
一线免疫检查点抑制剂联合化疗治疗肺肉瘤样癌疗效及安全性的评估
He Du,Xinyu Song,Fengying Wu
He Du
Background: Pulmonary sarcomatoid carcinoma (PSC) represents a rare subtype of non-small cell lung cancer (NSCLC), and it has poor pathologic differentiation, aggressive progression, and early metastasis. Conventional ant...
Clinical Trial
Lung Cancer (Auckland, N.Z.). 2025 Jun 9:16:73-83. DOI:10.2147/LCTT.S494990 2025
Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer Cells [0.03%]
解析FASN在敏感和耐药EGFR突变非小细胞肺癌干细胞中的作用
Emma Polonio-Alcalá,Sira Ausellé-Bosch,Gerard Riesco-Llach et al.
Emma Polonio-Alcalá et al.
Introduction: Cancer stem cells (CSCs) drive tumor initiation, relapse, and metastasis. Our research team developed polycaprolactone electrospun (PCL-ES) scaffolds for enriching lung CSCs (LCSCs) since monolayer culture d...
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154) [0.03%]
柳叶刀深度：III期LAURA研究——术后奥希替尼辅助治疗可切除IB至IIIA期EGFR突变NSCLC患者的疗效和安全性及FLAURA研究——奥希替尼对比对照组在不可手术的局部晚期或转移性表皮生长因子受体突变阳性非小细胞肺癌患者中的疗效和安全性
Faustine X Luo,Zhaohui Arter,Sai-Hong Ignatius Ou et al.
Faustine X Luo et al.
The current standard of care for unresectable stage III non-small cell lung cancer (NSCLC) involves a concurrent platinum-based doublet chemotherapy and chest radiotherapy, followed by consolidative therapy with durvalumab, an anti-programm...